Sep 19 2026 10:19 AM EST

Perrigo Posts Q2 2026 EPS Beat as Cost‑Saving Programs Offset Sales Decline

Perrigo Company plc (NASDAQ: PRGO) posted adjusted diluted earnings per share of $0.50 for the quarter ended June 27, 2026, surpassing the consensus estimate of $0.39. Net sales slipped 3.1% YoY to $1.023.8 billion, a performance that was in line with market expectations. The results prompted investors to reassess the company’s near‑term earnings outlook, especially after management reaffirmed FY 2026 guidance of adjusted EPS $2.25‑$2.55 and revenue $4.0‑$4.2 billion.

Quarterly Financial Highlights

Adjusted gross margin fell to 35.6% from 38.1% a year earlier, reflecting a 250‑basis‑point decline driven by lower pricing power and a mix shift toward lower‑margin categories. Adjusted operating margin slipped to 12.2% from 12.8% YoY, a 60‑basis‑point contraction. Operating cash flow for the quarter was $83 million, while capital expenditures were $14 million. Cash and cash equivalents stood at $399.7 million, down from $531.6 million at year‑end 2025. Total debt was $3.28 billion, yielding a debt‑to‑equity ratio of roughly 1.23.

Idiosyncratic Drivers: Divestiture and Cost‑Saving Programs

The completion of the Dermacosmetics divestiture in Q2 2026 generated cash proceeds of $359 million, which were applied to reduce the debt balance. While the sale reduced all‑in sales by roughly 3.2% YoY, the debt‑reduction benefit improves the balance‑sheet leverage profile. Concurrently, the company’s Operational Enhancement Program, part of the broader “Three‑S” plan, is on track to deliver annual gross pretax savings of $80‑$100 million by FY 2027. The program, which includes workforce reductions of about 7%, contributed to margin stability in the quarter.

Macro Context and Consumer Trends

Perrigo operates in a consumer‑health market that remains pressured by inflation‑driven value focus and seasonal softness in cough, cold and allergy categories, particularly in Europe. Retail inventory destocking is estimated to have removed about 1.8% of sales in the region. Currency translation provided a modest positive impact of roughly +0.3‑0.5% on both core and all‑in net sales. The company highlighted a sequential improvement in U.S. OTC volume in the four‑week period ending July 19, 2026, which it expects to support a stronger second half.

Segment Performance and Market‑Share Gains

Self‑Care sales fell 3.7% YoY to $577 million, while Specialty Care declined 2.8% to $227 million. Infant Formula was the only segment to post double‑digit growth, up 23.1% YoY to $101 million, reversing a prior year loss. Market‑share analysis showed a 1.5‑percentage‑point gain in U.S. store‑brand OTC volume versus a category decline of 1.1%, and a 3.3‑percentage‑point gain in key European brands versus a 0.6% category decline, each translating to roughly +50 bps of share.

Guidance Outlook and Investor Focus

Management reaffirmed FY 2026 guidance of adjusted EPS $2.25‑$2.55 and revenue $4.0‑$4.2 billion, implying a modest earnings recovery from the FY 2025 loss. The outlook assumes an effective tax rate of approximately 18%, down from the prior estimate of 20%, and incorporates an under‑absorption charge of roughly $0.60 per share for the full year, of which $0.18 was recognized in Q2 2026. Investors are watching the execution of the Operational Enhancement Program and the strategic review of the infant formula and oral‑care businesses for potential upside.